A reformulated version of an anti-HIV gel developed for vaginal use was found safe and acceptable by HIV-negative men and women who used it rectally, according to a Phase I clinical trial published today in PLOS ONE.
[More]
"Results of a major HIV prevention trial suggest that daily use of a product -- whether a vaginal gel or an oral tablet -- does not appear to be the right approach for preventing HIV in young, unmarried African women," a press release from the Microbicide Trials Network reports.
[More]
Three antiretroviral-based strategies intended to prevent HIV infection among women did not prove effective in a major clinical trial in Africa.
[More]
Gilead Sciences, Inc. announced today its results of operations for the fourth quarter and full year 2012.
[More]
Gilead Sciences, Inc. today announced that a Phase 2 clinical trial evaluating tenofovir alafenamide fumarate, an investigational novel prodrug of tenofovir for the treatment of HIV-1 infection, met its primary objective.
[More]
Several large clinical trials have demonstrated that a daily oral dose of one or two antiretroviral drugs used to treat HIV infection can prevent infection in an approach known as pre-exposure prophylaxis, or PrEP.
[More]
The U.S. Food and Drug Administration today approved Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate), a new once-a-day combination pill to treat HIV-1 infection in adults who have never been treated for HIV infection.
[More]
Gilead Sciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Stribild (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), a complete once-daily single tablet regimen for HIV-1 infection for treatment-naïve adults.
[More]
Gilead Sciences Inc. announced Thursday that it plans to partner with Mylan Inc., Ranbaxy Laboratories Ltd. and Strides Arcolab Ltd. "to promote access to high-quality, low-cost generic versions of Gilead's HIV medicine emtricitabine in developing countries," the Wall Street Journal reports.
[More]
Mylan Inc. today announced the establishment of a new agreement between its subsidiary Mylan Laboratories Limited and Gilead Sciences Inc. Under this agreement, Mylan has licensed the rights to produce and market generic versions of Gilead HIV/AIDS therapies containing Emtricitabine, including single and fixed-dose combinations.
[More]
GlobalPost's "Global Pulse" blog examines questions surrounding the use of the antiretroviral Truvada for pre-exposure prophylaxis (PrEP) to reduce the risk of HIV infection among people at high risk, as studies released and panel discussions held last week at the XIX International AIDS Conference (AIDS 2012) "raised concerns about the drug's effect on the future of the AIDS fight."
[More]
The international AIDS conference in Washington has already made two points clear. There is no prospect that scientists will any time soon find the ultimate solutions to the AIDS epidemic, namely a vaccine that would prevent infection with the AIDS virus or a "cure" for people already infected with the virus.
[More]
Gilead Sciences, Inc. announced today its results of operations for the quarter ended June 30, 2012.
[More]
Merck, known as MSD outside the United States and Canada, announced today that the company has signed two licensing agreements for investigational HIV drug candidates.
[More]
A large clinical trial testing the long-term safety and effectiveness of a new approach for preventing HIV in women - a vaginal ring used once a month - is now underway in Africa, researchers announced today at the XIX International AIDS Conference (AIDS 2012).
[More]
Warner C. Greene, MD, who directs virology and immunology research at the Gladstone Institutes, has joined with other global AIDS experts to release a locally affordable version of the world's leading AIDS medical textbook. Designed specifically for regions that today are hardest hit by the disease, this new text is the latest weapon in a growing arsenal aimed at curbing the spread of HIV/AIDS worldwide.
[More]
The story of the AIDS pandemic has been grim for so long that optimism seems hardly possible. But as the 19th International AIDS conference opens in Washington on Sunday, there is hope for control of a disease that has killed nearly 35 million people over three decades and 1.7 million in the past year.
[More]
Though South Africa has made progress against HIV/AIDS over the past few years, the country's "health minister says much more needs to be done," VOA News reports.
[More]
This has been a good week for breakthroughs in HIV/AIDS. Earlier this week, the Food and Drug Administration approved a daily pill, Truvada, which reduces the risk of HIV infection. Today, a University of Nebraska Medical Center research team's progress toward developing weekly or twice-monthly injectable antiretroviral therapy (ART) nanomedicines for patients with human immunodeficiency virus (HIV) infection will be highlighted as the cover story in the Journal of Infectious Diseases.
[More]
NPR's "Shots" blog reports on one of the drug trials considered by the FDA in its approval of the antiretroviral drug Truvada for pre-exposure prophylaxis (PrEP) to prevent HIV among people at risk of contracting the virus, which "was done at the Oswaldo Cruz Foundation Research Institute, also known as Fiocruz, in Rio de Janeiro."
[More]